24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso]

Verify with CMS →

mesalamine

RxCUI: 825134

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
0%
Plan Coverage
2
Plans Covering
T1
Avg Tier
0%
Prior Auth Required

What the CMS Formulary Data Shows for 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso]

Per the CMS 2026 Part D formulary file, 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso] (RxNorm concept RXCUI 825134, generic name mesalamine) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.

Real-world access to 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,717 Part D beneficiaries filled 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso] in 2023, with total plan-and-beneficiary spending of $6,835,481 and an average per-beneficiary annual cost of $3,981.06. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso] today.

Coverage Details

Formularies covering
1
Plans covering
2
Coverage rate
0%
Tier range
Tier 1, Preferred Generic
Average tier
Tier 1, Preferred Generic

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
100% of formularies

2023 Medicare Spending

Beneficiaries
1,717
Total spending
$6,835,481
Avg per beneficiary
$3,981.06

Tier Distribution Across Plans

2 plans
Tier 1, Preferred Generic

Medicare Advantage Plans (MA-PD) Covering 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso]

2 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Hamaspik Medicare Choice (HMO D-SNP) HAMASPIK, INC. T1 No $0 NY
Hamaspik Medicare Select (HMO D-SNP) HAMASPIK, INC. T1 No $34.50 NY

Frequently Asked Questions

Is 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso] covered by Medicare Part D?

Yes, 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso] is covered by 2 Medicare Part D plans (0% of all Part D formularies).

What tier is 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso] on Medicare Part D plans?

24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.

Does 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso] require prior authorization?

0% of Part D formularies require prior authorization for 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso]. Step therapy: 0%. Quantity limits: 100%.

How much does Medicare spend on 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso]?

In 2023, total Medicare Part D spending on 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso] was $6,835,481, covering 1,717 beneficiaries. The average spend per beneficiary was $3,981.06.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial